Clover Biopharmaceuticals Gets $66 Million from CEPI for COVID-19 Vaccine Trial

Chinese drugmaker Clover Biopharmaceuticals received a $66 million investment from the Coalition for Epidemic Preparedness Innovations (CEPI) to support clinical development and manufacturing of its COVID-19 vaccine candidate.

The funding will support early testing and the preparation of  sites for a global efficacy trial. CEPI anticipates providing more funding if the early stage clinical development is successful.

Clover’s S-Trimer is “a promising vaccine candidate with the potential to be scaled up to produce hundreds of millions or even one billion doses per year,” said CEPI’s CEO Richard Hatchett.